Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vernon F Schabert

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Epilepsy & Behavior : E&B|December 5, 2021
Indirect treatment comparison of cenobamate to other ASMs for the treatment of uncontrolled focal seizuresMichael Privitera, Florent F Richy, Vernon F Schabert
Biotechnology Healthcare|April 6, 2012
Patient medication adherence: the forgotten aspect of biologicsErica L Goldberg, Mitch Dekoven, Vernon F Schabert, et al.
The American Journal of Managed Care|April 10, 2009
Challenges for managing overactive bladder and guidance for patient supportVernon F Schabert, Tamara Bavendam, Erica L Goldberg, et al.
Current Medical Research and Opinion|July 30, 2008
Five-year routine cervical cancer screening rates and intervals in a US health planVernon F Schabert, Xin Ye, Ralph P Insinga, et al.
Journal of Managed Care & Specialty Pharmacy|March 26, 2016
What Contributes Most to High Health Care Costs? Health Care Spending in High Resource PatientsDaryl Pritchard, Allison Petrilla, Shawn Hallinan, et al.
Journal of Managed Care Pharmacy : JMCP|October 1, 2013
Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care populationVernon F Schabert, Crystal Watson, George J Joseph, et al.
Advances in Therapy|March 8, 2014
Treatment patterns following discontinuation of adalimumab, etanercept, and infliximab in a US managed care sampleJason Yeaw, Crystal Watson, Kathleen M Fox, et al.
Journal of Medical Economics|March 27, 2012
Exenatide BID and liraglutide QD treatment patterns among type 2 diabetes patients in GermanyLesley-Ann Miller, Chakkarin Burudpakdee, Anthony Zagar, et al.
Journal of Substance Abuse Treatment|July 4, 2006
Characterizing substance abuse programs that treat adolescentsTami L Mark, Xue Song, Rita Vandivort, et al.
Journal of Medical Economics|November 26, 2011
Annual costs of tumor necrosis factor inhibitors using real-world data in a commercially insured population in the United StatesVernon F Schabert, Crystal Watson, Shravanthi R Gandra, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Epilepsy & Behavior : E&B|December 5, 2021
Indirect treatment comparison of cenobamate to other ASMs for the treatment of uncontrolled focal seizuresMichael Privitera, Florent F Richy, Vernon F Schabert
Biotechnology Healthcare|April 6, 2012
Patient medication adherence: the forgotten aspect of biologicsErica L Goldberg, Mitch Dekoven, Vernon F Schabert, et al.
The American Journal of Managed Care|April 10, 2009
Challenges for managing overactive bladder and guidance for patient supportVernon F Schabert, Tamara Bavendam, Erica L Goldberg, et al.
Current Medical Research and Opinion|July 30, 2008
Five-year routine cervical cancer screening rates and intervals in a US health planVernon F Schabert, Xin Ye, Ralph P Insinga, et al.
Journal of Managed Care & Specialty Pharmacy|March 26, 2016
What Contributes Most to High Health Care Costs? Health Care Spending in High Resource PatientsDaryl Pritchard, Allison Petrilla, Shawn Hallinan, et al.
Journal of Managed Care Pharmacy : JMCP|October 1, 2013
Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care populationVernon F Schabert, Crystal Watson, George J Joseph, et al.
Advances in Therapy|March 8, 2014
Treatment patterns following discontinuation of adalimumab, etanercept, and infliximab in a US managed care sampleJason Yeaw, Crystal Watson, Kathleen M Fox, et al.
Journal of Medical Economics|March 27, 2012
Exenatide BID and liraglutide QD treatment patterns among type 2 diabetes patients in GermanyLesley-Ann Miller, Chakkarin Burudpakdee, Anthony Zagar, et al.
Journal of Substance Abuse Treatment|July 4, 2006
Characterizing substance abuse programs that treat adolescentsTami L Mark, Xue Song, Rita Vandivort, et al.
Journal of Medical Economics|November 26, 2011
Annual costs of tumor necrosis factor inhibitors using real-world data in a commercially insured population in the United StatesVernon F Schabert, Crystal Watson, Shravanthi R Gandra, et al.
Pageof 2